Pfizer Launches Global Innovation Challenge to Enrich the Lives of Patients Living with Metastatic Breast Cancer (mBC)

challenge-blog-post (2)

Did you know that an estimated 315,000 women in the U.S and E.U.1 are living with an incurable disease?2,3 The metastatic breast cancer (mBC) diagnosis can leave patients and their families experiencing uncertainty and significant emotional burden.4

Metastatic breast cancer is the most advanced type of breast cancer in which the tumor cells spread beyond the breast to other parts of the body, potentially affecting the bones, liver, lungs or brain.3 While progress in patient care has been made in the past decade, there is still a need for improvements in care and support among patients living with this disease. Pfizer is sponsoring the Advancing Care for Patients Living with mBC innovation challenge, in collaboration with Health 2.0, to encourage healthcare innovators to harness technology and develop cutting edge solutions that will help enrich the lives of patients living with metastatic breast cancer.

The challenge, Advancing Care for Patients Living with mBC, asks applicants to develop technology-enabled solutions to address one or more of the key patient needs below:

  • An intuitive, customizable, and tailored care management solution that improves care and disease management for patients living with mBC, incorporating a comprehensive approach to well-being across the care continuum
  • Solutions to support mBC patients with their daily living and enrich their lives
  • Solutions to help patients living with mBC engage and support one another

The challenge includes three phases. Phase I calls for the development of creative concepts that address key mBC patient needs, and submissions are due by January 20, 2017. Five semi-finalists will be selected from this round to move on to Phase II, where they will receive mentorship from industry experts to guide the development of their solutions. A mid-challenge pitch during this phase will determine the three finalists who will advance to Phase III. The finalists will demo their prototypes at a live pitch event in July 2017, where the grand prize winner will be selected.

A total of $250,000 in prize funding will be available to disruptive solutions with the greatest potential to enrich the lives of patients with mBC. With this challenge, Pfizer hopes to help close the gaps in mBC care and catalyze the development of meaningful solutions to support patients along the care continuum and improve their overall quality of life.

This is a global challenge that is open to developers, entrepreneurs, designers and innovators around the world! To learn more about the challenge and to submit an application, visit!

1 EU = Germany, France, Italy, Spain, UK

2 2016 CancerImpact KantarHealth

3 American Cancer Society. Detailed Guide: Breast Cancer. Accessed September 21, 2016.

4 Pfizer Inc. Global Status of Advanced/Metastatic Breast Cancer: 2005-2015 Decade Report. Published March 2016. Accessed September 26, 2016.

Leave a Reply

Your email address will not be published. Required fields are marked *